To summarize recent advances in IL-4 and IL-13 blockade in the treatment of asthma.
INTRODUCTION
Asthma is a clinically and physiologically heterogeneous disease characterized by chronic airway inflammation and obstruction. Recognition of distinct subclasses of asthma pathophysiologies has led to the notion of asthma as a collection of endotypes or disease pathophysiologies that share overlapping physiologic manifestations [1] . The identification of specific asthma endotypes coupled with the expanding knowledge of airway inflammation, epithelial and immune responses to allergens and viral infections has provided new opportunities for the development and application of endotype-specific therapies in the treatment of asthma. These same discoveries allow a more informative manner of classifying asthma that goes beyond symptoms, lung function and response to medications and could allow truly tailored therapy for an individual's unique pathophysiology [2] .
Allergic asthma, characterized by the presence of an immunoglobulin (Ig)E-mediated sensitization to one or more environmental allergens, represents the most common asthma endotype. Although the initial preconditions necessary for allergic sensitization are only partly understood, it is known that a cascade of Th2 cytokines, including IL-4, IL-5 and IL-13 among others, is necessary to initiate and propagate the inflammation associated with allergy. These cytokines are needed to induce class switching of B-cells to produce allergen-specific IgE (meditated by IL-4 and IL-13), recruit mast cells (IL-9) and eosinophils (IL-5) to sites of allergic inflammation and induce goblet cell metaplasia (IL-4, IL-13) [3] .
Inhaled corticosteroids (ICS) are a first-line medication in the treatment of asthma and are effective in a majority of patients. However, ICS therapy can be associated with significant sideeffects [4] and many patients with asthma are not well controlled with ICS therapy alone [4] . Also, there remains a group of between 5 and 10% of patients with asthma in whom corticosteroids in combination with long-acting bronchodilators are not sufficient in providing adequate symptom control [5] . This subgroup of asthmatics refractory to standard therapy are candidates for medications that target specific immunologic pathways, which have the potential to be both more effective and less toxic than oral ICS. However, the exquisite specificity of these medications require the development of biomarkers that will reliably identify patients that will maximally benefit from these therapies.
One successful example of this approach is omalizumab, a humanized monoclonal antibody (mAb) directed against free IgE, which was the first biologic asthma medication. Treatment with omalizumab is indicated for individuals with evidence of allergic sensitization to a perennial allergen and detectable serum levels of free IgE within a pharmacologically determined range. This approach allowed targeted treatment for allergic asthma rather than 'one-drugfits-all'. Using endotype specific biomarkers, which take into account the cause and pathophysiological mechanisms of disease pathogenesis, a targeted individualized approach to asthma care can be extended beyond omalizumab. In this review, we will discuss recent advances in biological therapies for asthma and the emerging role for endotype specific biomarkers to predict response to therapy.
ANTI-IL-4 THERAPY
IL-4 was simultaneously discovered in 1982 by groups led by Ellen Vitteta and William Paul. It was described as a soluble factor capable of both inducing B-cell proliferation and class switching [6] . Later, as the Th1 vs. Th2 paradigm developed, IL-4 was recognized as a key cytokine necessary to induce the differentiation of Th2 lymphocytes from naive T-cells and to help sustain the allergic response over time. Naturally, asthma, as a recognized manifestation of Th2 inflammation, became a target of investigation for anti-IL-4 therapy. Altrakincept is a recombinant human IL-4 receptor delivered by aerosol and intended to act as an antagonist to IL-4 action. Although preliminary studies of altrakincept in steroid-dependent, atopic asthmatics appeared promising [7] , efficacy could not be demonstrated in phase III trials [8] . Likewise, a humanized mAb targeting IL-4, pascolizumab [9] , was found to be ineffective in treating asthma [8] .
IL-13 BLOCKADE
The reason that anti-IL-4 did not show efficacy in atopic asthma in large part was likely because of the biological redundancy provided by IL-13. IL-4 and IL-13 are highly homologous to one another, are expressed by many of the same immune cell types and share many signaling pathways. There are two known receptors for IL-4, which are both heterodimers ( Fig. 1 ). The type 1 IL-4 receptor is composed of the common gamma chain (gC) and the IL-4Ra chain. The type 2 IL-4 receptor is composed of the IL-4Ra chain and the IL-13Ra1 chain and mediates signaling in response to both IL-4 and IL-13. There is also a second IL-13 receptor, IL-13Ra2, which binds IL-13 (but not IL-4) and may act as an inhibitory receptor [10] .
In addition to their shared functionality, IL-4 and IL-13 may play distinct roles in allergic inflammation. IL-4 is thought to signal primarily within the context of the immunologic synapse whereas IL-13 is responsible for more distant effects of allergic inflammation and may make IL-13 a more accessible therapeutic target [11] . The high degree of functional similarity between IL-4 and IL-13, in addition to the unique functions of IL-13, provided the scientific rationale for the development of a variety of anti-IL-13 therapies.
Perhaps the best studied of these therapies is lebrikizumab, a humanized IgG4 mAb that binds to IL-13 and blocks its action. Initial studies [12, 13] of this drug demonstrated a reduced late-phase asthmatic response in an allergen challenge study of 29 mild asthmatic patients. A larger double-blind placebo-controlled trial of 219 patients with uncontrolled asthma while on ICS [80% of whom were also taking a long-acting beta agonist (LABA)] showed that lebrikizumab improved FEV1 (forced expiratory volume in 1 second) across all treated patients compared with controls, although asthma symptom scores, as measured by the Asthma Control Questionnaire -5 (ACQ-5), were not improved. Significantly, periostin, a matricellular protein produced by respiratory epithelium in response to IL-13, differentiated individuals that responded to lebrikizumab. Those patients with a high periostin level
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Anti-IL-4/13 blockade appears to be most efficacious in patients with markers indicating underlying Th2 inflammation, such as increased eosinophils or periostin. experienced a greater improvement in FEV1 than those with a low periostin level. There was also a trend toward improved exacerbations in the high periostin group [14] .
A phase 2 study of 212 patients investigated the role of IL-13 and the effect of different doses of lebrikizumab in mild asthmatic patients not receiving ICS. In contrast to uncontrolled asthmatics receiving ICS, mild asthmatic patients demonstrated no meaningful changes in FEV1 between lebrikizumab treated and placebo groups (the primary outcome of this study). There was a statistical difference favoring lebrikizumab as to risk of treatment failure (defined as worsening asthma symptoms with a decline in lung function or increased pharmacologic therapy) at all doses compared with placebo (P < 0.001), although the degree of improvement would probably not be superior to ICS. Though patients with high periostin tended to have greater improvements in FEV1, this finding was not statistically significant and there was no difference in any outcomes on the basis of periostin levels [15 & ]. The value of measuring periostin as a signature of the Th2 induced asthma endotype, and its role as an indicator of expected beneficial response to therapy is an area of active investigation. Periostin has been demonstrated to correlate with airway eosinophilia in severe asthma [16] . Furthermore, in a study [17] of 224 patients with asthma treated with ICS, individuals with the highest levels of periostin appear more likely to have declines in lung function (FEV1). Given that periostin expression levels tend to decline in the airway epithelium of patients treated with ICS [18] , these studies suggest that high periostin in severe asthma may indicate ongoing Th2 inflammation despite ICS therapy. Studies addressing this hypothesis and the role of periostin in tracking treatment response will be needed.
Tralokinumab, another anti-IL-13 humanized mAb, was investigated in a phase 2 clinical trial of 194 patients aged 18-65 years with moderate-tosevere, inadequately controlled (ACQ-6 of >1.5) asthma despite daily ICS treatment. Patients were chosen to ensure more than 50% atopic patients and received either placebo or one of three doses of tralokinumab. Induced sputum was collected at the baseline and after 3 or 8 weeks of treatment. The primary end point, a reduction in ACQ-6 of at least 0.5, was not met, though patients receiving tralokinumab demonstrated less use of inhaled beta agonist. There was also a trend for an improvement in FEV1 (P ¼ 0.072). As with lebrikizumab, patients with evidence of active Th2 inflammation despite ICS therapy, in this case measured by sputum IL-13, tended to have the greatest response to tralokinumab [19] .
A pair of humanized IgG1 monoclonal anti-IL-13 antibodies has also been developed for the treatment of asthma [20] . Both IMA-638 (anrukinzumab) and IMA-026 bind IL-13, but recognize different epitopes on the cytokine and consequently block IL-13 interaction with different receptors. IMA-638 blocks binding of IL-13 to the IL-4Ra whereas IMA-028 inhibits binding of IL-13 to IL-13Ra1. When tested in an allergen challenge model of asthma (n ¼ 27, 29), IMA-638 was able to attenuate both the early-phase and late-phase allergic response at 14 days whereas IMA-028 showed only a nonsignificant improvement in the late-phase response. The investigators concluded that specifically blocking binding of IL-13 to the IL4Ra1, rather that the IL13Ra1, may be more effective in preventing allergic responses after allergen challenge.
Not all clinical studies with anti-IL13 therapy have shown evidence of clinical improvement. GSK679586 is a humanized IgG1 mAb that initially showed positive effects on measures of lung inflammation (fractional exhaled nitric oxide, FeNO) when studied in a phase I trial of mild asthmatic patients [21] . In a placebo-controlled study [22 & ] of 198 patients with poorly controlled, severe asthma on maximal doses of inhaled corticosteroids, patients were randomized to receive either GSK679586 or placebo. Over the course of the study, there was no clinically significant improvement in the primary outcome (ACQ-7) or FEV1. Attempts to stratify the patients post hoc by serum IL-13 levels or blood eosinophil levels (both markers of Th2 inflammation) did not show an effect of GSK679586, although periostin and FeNO data were not collected. The authors provided several possible reasons for the contrast in efficacy of GSK679586 compared with other anti-IL-13 therapies. Chiefly, it appears that, in contrast to other studies of anti-IL-13 therapies discussed above, GSK679586 was directed at the most severe asthmatic patients receiving maximal doses of ICS, who were less likely to respond to anti-IL-13 therapy. Another explanation was that GSK679586 inhibits binding of IL-13 to the IL13Ra1, and therefore, like IMA-028, may be less effective than therapies targeting IL-13 binding to the IL-4Ra1. Alternatively, the potency and/or dose of GSK679586 may have been inadequate to provide a therapeutic effect in this population.
DUAL BLOCKADE OF ANTI-IL-4 AND IL-13
The overlapping nature of IL-4 and IL-13 signaling pathways also presents opportunities to inhibit the action of IL-4 and IL-13 simultaneously. One such medication is pitrakinra, a variant of the IL-4 protein that contains two amino acid changes that allows pitrakinra to bind the IL-4Ra chain, without allowing it to complex with either the gC or IL-13Ra1 chains. Binding by pitrakinra results in inhibition of both IL-4 and IL-13 signaling. In an allergen challenge study [23] examining both subcutaneous injection (n ¼ 32) and nebulized pitrakinra (n ¼ 32), nebulized pitrakinra resulted in a decrease in the late-phase allergic response measured by FEV1. A later study [24] revealed a pharmacologic interaction between therapy and variation within the gene encoding the IL-4Ra chain (IL-4RA), identifying an asthma subgroup that was more responsive to pitrakinra.
In a larger study of 534 symptomatic moderateto-severe adult (>18 years) asthmatic patients using corticosteroids, participants were randomized to inhaled pitrakinra or placebo. Patients were stabilized for 4 weeks on LABA and ICS, and then randomized to pitrakinra or placebo for a 12-week treatment period. LABA was removed at day 28 and ICS were tapered starting on day 42 and halted on day 70. The results of the study [25] revealed that although there was no therapeutic benefit for the entire population treated with pitrakinra compared with placebo, non-Hispanic white patients with a common genotype had a significant dose-dependent reduction in asthma exacerbations along with decreased nocturnal awakenings and improved limited activity. This larger study did not confirm the role of polymorphisms identified in the earlier study.
Another strategy that has been utilized to block Th2 signaling is to target IL-4Ra with a mAb, and thus block both IL-4 and IL-13 signals. AMG-317 is a high affinity IgG2 mAb targeting IL-4Ra. A phase 2, randomized, double-blind, placebo-controlled trial was performed to test the effectiveness of AMG-317 in 294 moderate-to-severe asthmatic patients receiving ICS therapy [26] . After 12 weeks of therapy, all tested doses of AMG-317 failed to achieve a significant improvement in ACQ score (as the primary end point), although some benefit was noted in patients with the worst baseline ACQ scores and in the number of exacerbations experienced by patients receiving AMG-317. Interestingly, the authors speculated that heterogeneity of the study population was a contributor to the poor overall response to AMG-317 and that a subset of patients may benefit from therapy: patients with higher airway reversibility appeared to have better responses to therapy.
Like AMG-317, dupilumab is a fully humanized mAb to the IL-4Ra receptor that inhibits both IL-4 and IL-13 [27 && ]. A phase 2A study of 104 moderateto-severe asthmatic patients were randomized to receive dupilumab or placebo. Interestingly, all patients had to have a peripheral eosinophil count of 300 cells/ml or at least 3% sputum eosinophilscriteria that excluded over half of all patients assessed. After randomization, there was a 12-week intervention period that included a steroid reduction phase followed by an 8-week follow-up period. The primary end point, occurrence of asthma exacerbation during the 12-week intervention phase, was met with an 87% reduction in the proportion of dupilumab-treated patients with an asthma exacerbation. FEV1 was improved at week 2 and was maintained through week 12 despite discontinuation of LABA and inhaled glucocorticosteroids. Multiple other outcomes met significance, including change from the baseline at week 12 in ACQ5, morning and evening asthma symptom scores, nocturnal awakenings and of inhalations of rescue beta agonist.
CONCLUSION AND FUTURE OF ANTI-IL-4/ 13 THERAPIES
Anticytokine therapies for the treatment of atopic diseases may be a part of the future of allergy and particularly asthma care. Despite early setbacks, there are now several anti-IL-13 and anti-IL-4/13 therapies that appear promising. Demonstration of clinical efficacy of these medications is closely linked to the improved ability to define an individual's asthma endotype -or specific asthma pathogenesis. This new paradigm in the treatment of asthma is similar to the treatment of cancer in which a combination of phenotypic markers, such as histology, genetics and demographics, can be used to optimize therapy.
The observation that the efficacy of pitrakinra is exquisitely sensitive to genetic polymorphisms within the IL-4Ra suggests that detailed genetic studies may help identify patients that will benefit from therapy. Dupilumab, like IL-4a, also acts by binding to IL-4Ra, raising the possibility that IL-4Ra polymorphisms may have a pharmacologic interaction with dupilumab. Bispecific antibodies, antibodies that are able to inhibit the action of two substrates simultaneously, have been designed for IL-4 and anti IL-13 and could be an additional therapeutic option in individuals with an unfavorable IL-4Ra polymorphism [28] .
Given the common pathogenesis of many atopic diseases, the potential application of anti-IL-4/13 therapies outside of asthma is exciting and reports of dupilumab in the treatment of atopic eczema are promising [29 && ], but the roles of other anticytokine therapies in nonasthma atopic disease need to be studied. Studies to better define the pathogenesis and propagation of nonatopic forms of asthma need to be performed in order to find appropriate endotype specific biomarkers and to identify new therapeutic drug targets. Likewise, anti-IL-4/13 therapies hold promise in the treatment of a variety of diseases in which Th2 cytokines have been implicated, such as interstitial lung disease [30] .
